Strategy, advocacy and partnering for the orphan drug industry

14-15 November 2017
Pre-Congress Workshops: 13 November
Fairmont Rey Juan Carlos Barcelona, Spain

Created by Including Part of

#wodceurope terrapinn.com/orphandrugeu17
THE ORPHAN DRUG LANDSCAPE IS CHANGING

The 8th World Orphan Drug Congress is taking place 13 - 15 November, Barcelona and is not an event to be missed. Now recognised as the largest and most established European orphan drug event, we are once again proud to deliver another fantastic speaker line up and content filled agenda that represents the whole orphan drug scene. The 8th annual event will address the strategic and commercial aspects of bringing new treatments to patients who suffer from rare diseases. You’ll notice that the Patient Advocacy Track is no longer here, it’s because we’ve integrated the patient voice in every part of the whole agenda.

We thank our Advisory Board members for their contribution to the agenda this year:

- **Professor Michael Linden**
  Former VP Gene Therapy & Head, GMI Pfizer

- **Yann Le Cam**
  Chief Executive Officer
  EURORDIS - Rare Diseases Europe

- **Dr Ségolène Aymé**
  Founder of Orphanet & Rare Disease Expert in Residence, ICM

- **Dr Bruno Sepodes**
  Chair of COMP EMA

- **Alastair Kent**
  Director
  Genetic Alliance UK

- **Nicole Boice**
  Founder & CEO
  Global Genes

- **Dr Carlo Incerti**
  SVP, Head of Global Medical Affairs, CMO Genzyme

Book your place early for the best rates [terrapinn.com/orphandrugeu17](http://terrapinn.com/orphandrugeu17)
AGENDA OVERVIEW – WHAT’S NEW IN 2017?

PRE-Congress Workshops - 13th November 2017

MORNING PRE-Congress Workshop

Pricing, Reimbursement and Market Access Challenges for Orphan Drugs and Cell and Gene Therapies

Hosted by

Pre-congress workshops on the 13th November will give you a full days’ worth of content where you get the chance to learn topics from health economics, payer and evidence generation to unique challenges in regulation, pricing, reimbursement & market access for cell and gene therapies for rare diseases - pick this option on your registration to join

AFTERNOON PRE-Congress Workshop

Assuring success from Regulatory to Global Market Access of Rare Disease Treatments

Hosted by

DAY 1 - 14th November 2017

PLENARY SESSIONS

Plenary discussion on best practices to generate pre and post-launching data – the value of shared governance of registries from an international registry, regulator and pharma perspective – don’t miss out!

Keynote sessions from the ORPH-VAL working group, using best practice European principles to assessing the value of orphan medicines. Join us with UK and Germany HTA representatives in correcting the access discrepancy between countries

LUNCH

Patient Access

The value of ODs. Join our hard hitting access & pricing talks with HTA perspectives from UK, Spain and Germany as well as industry experts form Sobi, IMS, Dxiion and more

CLINICAL DEVELOPMENT

Progress your treatment with relevant clinical endpoints, navigate through the approval process and design innovative trial designs by hearing from Albion, Takada, Bluebird Bio, Premier Research, PRA Health Sciences, INC Research and more

GENE THERAPY

Two days of Gene Therapy sessions – the sector has grown tremendously in the last few years. How would you price a cure and manufacture a gene therapy sustainably? Hear from NHS England, Pfizer, Biomarin, Chiesi, Genethon, Orchard Therapeutics, ReGenXBio, Lysogene, Abeona Therapeutics and plenty more

SCIENCE & STRATEGY

Combining Science & Strategy is what our congress does best, which is why we have invited high-level speakers to give us insights into their business model, patient engagement methods and the impact of precision medicine from Findacure, AbbVie, Action Duchenne, Merck, RARE Science, Armehtion, Caribou Biosciences, Collectes Therapeutics, GW Pharmaceuticals & many more

ROUNDTABLES

Pre-Congress Workshops on the 13th November will give you a full days’ worth of content where you get the chance to learn topics from health economics, payer and evidence generation to unique challenges in regulation, pricing, reimbursement & market access for cell and gene therapies for rare diseases - pick this option on your registration to join

LUNCH

NETWORKING BREAK

PRODUCT DEVELOPMENT

How is collaborative research and partnerships translated into products? Hear from Fondazione Telethon, Italy experience with Shire, Biomarin and GSK, as well as how a charity-industry consortium have worked together to provide meaningful advice to HTAs.

GENE THERAPY

Two days of Gene Therapy sessions – the sector has grown tremendously in the last few years. How would you price a cure and manufacture a gene therapy sustainably? Hear from NHS England, Pfizer, Biomarin, Chiesi, Genethon, Orchard Therapeutics, ReGenXBio, Lysogene, Abeona Therapeutics and plenty more

PITCH & PARTNER

New investors in the Pitch & Partner track will help biotechs and academics understand how to gain capital and progress their treatments

SCIENCE & STRATEGY

Combining Science & Strategy is what our congress does best, which is why we have invited high-level speakers to give us insights into their business model, patient engagement methods and the impact of precision medicine from Findacure, AbbVie, Action Duchenne, Merck, RARE Science, Armehtion, Caribou Biosciences, Collectes Therapeutics, GW Pharmaceuticals & many more

BOOK YOUR PLACE EARLY FOR THE BEST RATES terrapinn.com/orphandrugu17
MORNING
PRE-CONGRESS WORKSHOP
13TH NOVEMBER

HOSTED BY MME

9:00 – 12:30
Pricing, Reimbursement and Market Access Challenges for Orphan Drugs and Cell and Gene Therapies

09:00 - 09:15
Introductions
Dr Renato Dellamano, President, MME Europe
Doug Paul, Partner, MME

09:15 – 10:15
Orphan Drugs and Advanced Therapy Medicinal Products (ATMPs) in the EU: Pricing, reimbursement and market access challenges
Dr Renato Dellamano, President, MME Europe

10:15 – 10:30
Coffee Break

10:30 – 11:30
A Company’s perspective – Chiesi’s experience with Orphan Drugs – Enzyme Replacement Therapies and ATMPs
Tiziana Magni, Global Pricing & Market Access Specialist, CHIESI FARMACEUTICI SPA
Davide Finocchiaro, Global Pricing & Market Access Specialist, CHIESI FARMACEUTICI SPA

11:30 – 12:30
Guided panel discussion – What pricing, reimbursement and market access models for Orphan ATMPs? Addressing the following key questions:
What should be the key driving factors to consider for pricing decisions?
• Can current HTA approaches work in the assessment of Orphan ATMPs?
• What reimbursement and funding models should be adopted?
• How should PR & MA approaches for Orphan ATMPs be adapted in different health systems?
Doug Paul, Partner, MME

12:30
Networking Lunch followed by afternoon workshop

Book your place early for the best rates terrapinn.com/orphandrugeu17

AFTERNOON
PRE-CONGRESS WORKSHOP
13TH NOVEMBER

HOSTED BY Mapi

Assuring success from Regulatory to Global Market Access of Rare Disease Treatments
13:40 – 14:30
Partnering with patients for clinical success
• This interactive workshop will introduce participants to a 360° approach to obtaining patient insights and applying them for the successful design and execution of clinical studies. Through engaging activities, we will address how to get to the heart of the patient’s decision-making process, assess their physical/emotional/social needs, and identify their motivators, barriers and influencers as they relate to clinical study participation.
• Participants will then learn how insights are analysed and applied in order to:
  o Design studies that appeal to the targeted patients
  o Determine effective and motivating recruitment methods
  o Engage and communicate with patients and caregivers
  o Identify retention methods that meet the needs of a specific patient population
  o Develop materials that resonate with patients and caregivers
Kelly Franchetti, Vice President Global Patient Insights and Engagement, Patient Centered Sciences, Mapi Group

14:30 – 15:30
Methodologies in developing Real World Data: Engaging stakeholders in developing evidence strategies
How is expanded access used to provide treatment for patients with rare diseases?
• Compassionate Use Programs in the window between submission and commercialization
• What are the benefits of conducting clinical studies and registries for rare diseases?
• What are the types of studies conducted during different phases of orphan drug development?
• How are patient registries used to generate real-world data for rare diseases and orphan drugs?
• Ethical Patient Warehousing – working with Advocacy to identify populations in advance of research
• What are the unique challenges of conducting rare disease/orphan drug registries?
• How can proactive study management strategies successfully address these challenges?
• Potential risk mitigation strategies, and alternative registration strategies will be discussed
Dr Will Maier, Chief Scientific Officer and Head of Patient-Centered Sciences, Mapi Group

15:30 – 16:00
Coffee Break

16:00 – 17:00
An introduction to the science of endpoint design in the current regulatory and HTA environment in the US and Europe
• Regulatory strategies for early scientific advice: FDA & EMA scientific advice, PRIME & adaptive pathways link to scientific advice
• The creation, categorization and hierarchy of endpoints and requirements of different stakeholder groups, including: regulatory agencies, clinicians, HTA bodies, payers, increasingly active patient groups
• Real-life examples of endpoints used in selected therapeutic area & techniques for the development and validation of new endpoints
• Highlighting guidance and publications that will be of use to newcomers to the area
• Solving the non-alignment between different agencies and geographical differences in approach
Rory Graham, Senior Director, EU Regulatory Services, Mapi Group
Martine Zimmermann, Global Head of Regulatory Affairs, Alexion pharma GmbH

17:00
End of Workshop Followed by Networking Drinks Hosted by Mapi Group
TUESDAY, 14TH NOVEMBER

OPENING KEYNOTE PLENARY

08:50 Chair’s opening remarks

Wills Hughes-Wilson
Former Senior Vice President, Chief Patient Access Officer
Sobi

Plenary discussion: ORPH-VAL Using best practice European principles in assessing the value of orphan medicines: Correcting the discrepancy between countries

• How do these principles compare to the criteria that current countries use?
• Opportunity for different European payers-HTAs to openly suggest what is realistic and why
• Creating a harmonised and sustainable model adapted to rare diseases
• How is it acceptable that each country has a different post-marketing criteria?
• What are the interests of payers and HTA bodies when considering how to improve access to rare disease therapies?

Speaker:
Sheela Upadhyaya
Associate Director Highly Specialised Technologies
NICE

09:00 Payers & HTAs feedback on best practices:

Dr Edmund Jessop, Medical Advisor, Specialised Commissioning Team, NHS England

09:50 Current state of the art in multi-stakeholder and international collaborative processes for shared registries: The importance of early dialogue initiatives & expedited regulatory pathways

• Encouraging bigger and more innovative collaboration approaches between pharma, patient and academic organisations
• Good practices to generate pre and post-marketing data – the value of shared governance of registries
• Possible solutions and guidance to the regulatory requirements and standardisation of registry data

Speaker:
Jim SanSPAN
Member of the Cross Committee Task Force on Registries and Rare Disease Management Policy
Medicines Evaluation Board, The Netherlands

Dr Heide Stirnadel-Farrant, Director, Real World Evidence & Reimbursement
Jan Span, Member of the
International Niemann-Pick Disease Alliance, UK

10:30 Networking refreshment break

11:30 INTERACTIVE ROUNDTABLES: See page 8

13:00 Networking lunch & poster session

14:15 Chair opening remarks: Tara O’Maire, VP, Clinical Development Operations, Incyte

Gene Therapy: Challenges to accelerate clinical progression for gene therapy products

Wills Hughes-Wilson, Former SVP, Chief Patient Access Officer, Sobi

Dr Heide Stirnadel-Farrant, Director, Real World Evidence & Reimbursement
Jan Span, Member of the
International Niemann-Pick Disease Alliance, UK

15:15 Tailoring drug development to meet an evolving orphan drug assessment landscape

Early access to orphan medicines – a glimpse into the future

Ron Fox, Head of Business Development, Clinigen Group

16:40 Innovative strategies for clinical development for genetic rare disease

Judith Rg-Cahalin, Chief Scientific Officer, INC Research/InVivo Health

Embracing real-world evidence as a tool to demonstrate effectiveness beyond the clinical trial

Stella Blackburn, VP, Global Head of Early Access & Risk Management, Real World Evidence Solutions, QuintilesIMS

17:00 Incorporating the patient voice into the rare disease therapeutic development process

Juliet Mottz, Executive Director, Patient Engagement & Strategic Development, Premier Research

Assessing the Value of Immunotherapy (IO) Drugs – Integrating patient data

Patrick Hopkinson, Executive Director, Wunderman Thompson, IMS

17:25 Spinal Muscular Atrophy - Bringing the first treatment to patients

Robert Bezaz, Ela (Head of Medical Affairs, SMA, Biogen)

Discussion: Examining the challenges of valuing payers and HTAs

Wills Hughes-Wilson, Former SVP, Chief Patient Access Officer, Sobi

Patrick Hopkinson, Executive Director, Wunderman Thompson, IMS

17:50 Overcoming patient recruitment & trial design challenges to accelerate clinical progression for gene therapies

Tara O’Maire, VP, Clinical Development Operations, Bluebird Bio

The future of gene therapies for rare disease: Managing the rapid progression of gene therapies

Nadia Bodkin, Senior Director, Innovative Contracting, University of South Dakota

18:15 Chair’s closing remarks

Dr Ana Mingeras, Principal, Orcanea Consulting

18:30 Networking Drinks
ROUNDTABLES

Covering a number of hot topics and delivered by patient groups, sponsors and leading solution providers, choose which two roundtable discussions you would like to join, for ‘off the beaten track’ learning and information you can’t find online. Each session will last 45 minutes so you can join two discussions in the allotted time.

PRODUCT DEVELOPMENT CHALLENGES

Round 1: Bringing clinical trials directly to patients: Solutions to reduce the burden of clinical trial participation
Scott Schliebner, Vice President, Scientific Affairs, PRA Health Sciences

Round 2: Rare disease patients as consumers: Latest strategies to engage and include patients in the clinical development ecosystem
Scott Schliebner, Vice President, Scientific Affairs, PRA Health Sciences

ACCESS & MARKET CHALLENGES

Round 1: How certain should we be before we make medicines available?
Dr Paul Robinson, Executive Director, Medicine & Patient Perspectives, MSD

Round 2: How Managed Access Programs (pre commercial supply to patient’s with unmet medical needs) can be a valuable component of launch strategy for orphan drugs
Robert Donnell, Director of Business Development, Durbin

Visit the website for most up to date agenda terrapinn.com/orphandrugeu17
WEDNESDAY, 15TH NOVEMBER

OPENING KEYNOTE PLENARY

08:30
Chair’s opening remarks

Wills Hughes-Wilson
Former Senior Vice President, Chief Patient Access Officer
Sobi

08:35
Executive industry discussion: Intentions of pharmaceutical companies developing treatments for rare disease patients – What do they hope to achieve?

• The evolving role of pharma and multi-stakeholders
• What are the challenges?
• What are the options moving forward?
• How do we work together to improve this?

Questions:
Key Parkinson, CEO, Cambridge Rare Disease Network, Director, Alston
Europe, Founder, Alston Syndrome UK

Pierre Lurin, CEO, Prometic

Mauro A. Nino, Head of Medical Affairs for Europe, Genzyme

Scott Pescaut, Oncology General Manager Rare Diseases, Novartis

Dr Mathew T. Pothier, Head of Rare Disease - Discovery, Roche Pharma Research and Early Development

09:30
Case study: Moving Mountains: How one parent led charity raised and spent millions, accelerating research and impacting the landscape

• Developing innovative and holistic funding model to accelerate trials in rare disease
• Leveraging investment model to bridge the “valley of death”
• How we did it

Emily Crossley, Co-founder and Joint CEO, Duchenne UK

09:55
Introducing a new industrial player emerging from a patient organisation, for the industrialisation of cell & gene therapies to be commercialised at a fair price

• Materializing research outcomes into products
• The role of a patient group, APN-Thealoon from innovation to production
• Ability to provide production to pharma and biotech
• Using new models to give a fair opportunity to all stakeholders

Dr Frederic Reval, Chief Executive Officer, Genethon, President, Yponsaki

10:20
Networking refreshment break

10:25
INTERACTIVE ROUNDTABLES; See page 11

12:05
Networking Lunch & Patient Poster Session

13:40
An update on Fondazione Telethon’s multi-stakeholder collaborative model with pharmaceutical/biotech companies and the success story and strategy leading to Strimvelis

Dr Lucia Facoli, Head of Research Development Office, Fondazione Telethon, Italy

Dr Sègolène Aymé, Founder of Orphanet, Rare Disease Expert in Residence, ICM

Yann Le Cam, Chief Executive Officer, EURORDIS - Rare Diseases Europe

14:10
A panel discussion on an innovative and groundbreaking collaborative approach to approaching HTA in rare disease

• Project HERCULES: A platform to share evidence to HTAs - a model for CMD and beyond

Josie Godfrey, Former Associate Director - High Specialised Technologies, NICE

Emily Crossley, Co-founder and Joint CEO, Duchenne UK

Fleur Chandler, Therapeutic Area Head, Respiratory, Orphan Evidence and Outcomes at GSK, Representing at Chair Steering Committee at Duchenne UK

Joris Clayton, Vice President and General Manager for United Kingdom and Ireland, PTC Therapeutics

14:50
The potential of gene editing therapies for orphan diseases: Is gene therapy the best way forward?

• The current state of CAR/CRISPR gene editing technology
• Empowering evolutionary gene editing technology to treat monogenic rare diseases
• The opportunities and the challenges

Dr Arnold Munirzik, Co-founder, Imagine Foundation

15:05
Presenting IRDRC’s 2027 vision and goals

Dr Diego Ardigò, Chairman, Therapies Scientific Committee (TSC) IRDRC & Project Lead, Chiesi Group

Dr Mathew T. Pothier, Head of Rare Disease - Discovery, Roche Pharma Research and Early Development

15:20
Pitch & Partner 4

Woody Bryan, Senior Vice President, Business Development and Licensing, Sucampo Pharmaceuticals Inc

Pitch & Partner 3

BRAINCVISURES PLATFORM: A road for intelligent repurposing, drug discovery and personalized medicine

Dr Krzysztof Potemka, Founder, Braincures

15:35
Networking refreshment break

16:05
Avoiding the road blocks to allow accelerated repurposed drugs to patients

Dr Michale Boskilla-Chubb, Head of Business Development, Healx

Dr Mathew T. Pothier, Head of Rare Disease - Discovery, Roche Pharma Research and Early Development

Pitch & Partner 5

Disulfiram – An anti-alcoholism medicine will give cancer patients new hope

Dr Weiguang Wang, MD, PTC Therapeutics

16:20
Pitch & Partner 6

Massive parallelization of drug discovery with AI-enabled phenomics

Dr Ronald Atta, Director of Translational Biology, Recursion Pharmaceuticals

Pitch & Partner 7

Grafting Yields addiction therapy

Dr Diego Ardigò, Chairman, Therapies Scientific Committee (TSC) IRDRC, Project Lead, Chiesi Group

16:55
Paediatric drug development: The interaction between industry, physicians and patient groups to get the drug into the market and subsequent P&R approval

Marek Ostrowski, Director Science and Regulatory policy, Novartis

17:05
Chair closing remarks

17:10
End of Congress

NOTICE: This document is a draft and may be subject to change.
COVERING A NUMBER OF HOT TOPICS AND DELIVERED BY PATIENT GROUPS, SPONSORS AND LEADING SOLUTION PROVIDERS, CHOOSE WHICH TWO ROUNDTABLE DISCUSSIONS YOU WOULD LIKE TO JOIN, FOR ‘OFF THE BEATEN TRACK’ LEARNING AND INFORMATION YOU CAN’T FIND ONLINE. EACH SESSION WILL LAST 45 MINUTES SO YOU CAN JOIN TWO DISCUSSIONS IN THE ALLOTTED TIME.

**REGIONAL PROVISIONS, PATIENT ENGAGEMENT & PRECISION MEDICINE**

- **Developments in Eastern Europe: Unique challenges and opportunities**
  - Pawel Wozniak, Managing Director, Komtur Polska

- **The future of a fully integrated multi-stakeholder model – what can we learn from USA advocate perspective?**
  - Debbie Drell, Director of Membership, NORD

- **Differences in registration and reimbursement in the Nordic markets**
  - Einar Andreassen, Senior Adviser, Norwegian Medicines Agency
  - Dr Douglas Lundin, Chief Economist, TUV Dental and Pharmaceutical Benefits Agency, Sweden

- **How to develop a platform to unite clinical research on paediatric rare diseases**
  - Begonya Nafria Escalera, Patient Advocacy Manager, Sant Joan de Deu Children’s Hospital

- **Marketing Authorization requirements**
  - George Reynolds, COO, Vitro Software

- **Differences in registration and reimbursement in the Nordic markets**
  - Einar Andreassen, Senior Adviser, Norwegian Medicines Agency
  - Dr Douglas Lundin, Chief Economist, TUV Dental and Pharmaceutical Benefits Agency, Sweden

- **How to develop a platform to unite clinical research on paediatric rare diseases**
  - Begonya Nafria Escalera, Patient Advocacy Manager, Sant Joan de Deu Children’s Hospital

- **A guide to effective patient submissions for HTA processes**
  - Sandra Nestler-Parr, Director of Rare Access and as Trustee of Alpha-1 UK Support Group
  - Sheila Upadhyaya, Associate Director, Highly Specialised Technologies, NICE

- **First-hand experience as a patient representative: Making a difference from trial design to access negotiations in orphan drugs**
  - Dr Jasmin Barman, Scientific Advisor, Swiss Society for Porphyria

**PATIENT ENGAGEMENT & PRECISION MEDICINE**

- **ADCYS-related Dyskinesia case study: How research and clinical advancements occur through engagement of the rare disease patient community**
  - Christina Waters, CEO and Founder, RARE Science

- **How we can ensure rapid development of gene therapies for rare diseases by working with patients and patient organisations?**
  - Emily Culme-Seymour, External Strategy Manager, Gene Therapy, GSK

- **GOSgene: Enabling innovation through gene discovery - Application of precision medicine within rare disease development**
  - Dr Hywel Williams, Senior Research Associate, The Centre for Translational Omics – GOSgene, Genomics and Systems Medicine, UCL, GOS Institute of Child Health

- **A guide to effective patient submissions for HTA processes**
  - Sandra Nestler-Parr, Director of Rare Access and as Trustee of Alpha-1 UK Support Group
  - Sheila Upadhyaya, Associate Director, Highly Specialised Technologies, NICE

- **First-hand experience as a patient representative: Making a difference from trial design to access negotiations in orphan drugs**
  - Dr Jasmin Barman, Scientific Advisor, Swiss Society for Porphyria

Visit the website for most up to date agenda terrapinn.com/orphandrugeu17
HOW WILL OUR SPONSORS & EXHIBITORS BENEFIT?

Over the course of the meeting in Barcelona all the sponsors and exhibitors will benefit from direct F2F access with over 450 delegates, where in total there will be over 8 hours of networking sessions taking place. Different levels of partner involvement and activities offer the following:

PRESENTATIONS
High level sponsors are able to give full speaker case study presentations directly to potential and existing clients reinforcing their credibility and demonstrating thought leadership on specific topic areas.

EXHIBITION
With 30 exhibitors in total in 2016, they all have a unique opportunity to put their business products and services in front of potential buyers looking to source the latest technologies in the industry. This enables our clients to generate a high level of sales leads and form strong new relationships. All the complimentary buffet lunches and refreshments take place in this room, ensuring potential clients are in touching distance at all times when not in the conference.

HOST A ROUNDTABLE
On one of the days sponsors will have the opportunity to host/moderate one of the Roundtables discussions on a topic of their choice for 45 minutes. The session is part of the conference agenda so all attendees will see the topics and choose the tables of most interest to the subject matter, ensuring the sponsor will be in direct F2F discussion with 15-20 of the most relevant attendees at the event. Topic choices are based on a first come first served policy and naturally we won’t be duplicating topic areas, so if you want to guarantee your topic focus area please let us know asap to avoid disappointment.

BRAND AND POSITIONING
Through the associated company logo visibility on our banners and event marketing information on-stand, the sponsors and exhibitors in Barcelona will be able to build their brand and positioning within the orphan drug industry. This in turn will help them be seen as a leading solutions and service provider to new and existing customers, as well aligning themselves with industry bellwethers.

DRINKS RECEPTION
The drinks networking receptions at the end of each day will offer everyone the chance to unwind and relax in a more informal setting, developing further the business relationships that are initiated during the day.

NETWORKING MANAGER
As a high level sponsor there is the opportunity to have your own private networking manager for the event, who will work closely with you to facilitate and arrange 1-2-1 business meetings at the event. They will send out the attendee list approx. 4 weeks prior for the sponsor to choose pre-qualified targeted clients, and we will then assist pre-event and on-site for your team to have those meetings in your own reserved private meeting space.

JUBLIA NETWORKING SYSTEM
Jublia is our dedicated online networking tool used at the event by all the attendees, ensuring everyone focuses their time in valuable conversations and meetings with the right people for their business. It will be used at the event to ensure delegates manage their time onsite efficiently, can find attendees who share the same interests, can search for individuals by industry, company or name, can send and receive emails to the people they’d like to get in contact with, and set up their onsite meetings. Delegates are able to target and arrange to meet everyone they want to before the event begins via the on-line portal.
THE EXHIBITION

Here’s an overview of the floor plan. See the website for the most up-to-date version.

**YOUR CUSTOMERS WILL BE THERE TO:**
- Hear insights from the world’s leading thinkers, practitioners and process disrupters
- Evaluate and buy the latest technologies
- Create new partnerships and gain investment
- Have fun and do business

**WHAT THIS MEANS FOR YOUR BUSINESS:**
Emerging science, technologies and collaborations are needed to make the necessary moves forward. As a provider of solutions to these issues, the event will provide a space for you to get in front of potential new customers from all walks of the orphan drug industry.

**WHAT A GREAT OPPORTUNITY TO:**
- Debut new solutions
- Improve your brand awareness
- Meet new prospective clients
- Maintain relationships

**PURSUE AND PARTNER**
- Thousands of formal and informal meetings over just three days
- 30+ scientific posters
- Three engaging networking lunches
- Two networking drinks receptions

---

**Who should sponsor?**

- Pharma
- Biotech
- CROs
- Market Access
- Consultancies
- CMOs
- Platform Technology

---

To exhibit, sponsor or speak, please call **Andrew Mears** on **+44 (0) 207 092 1228** or email **andrew.mears@terrapinn.com**
SUPPORTING PARTNER & SPONSORS

MME
Cello Health
Complete Healthvizont
DOLO
Durbin
Komtur Polska
Global Care Clinical Trials
raremark
Scherenmark kiehbrau collection
CIB
WORLDWIDE CLINICAL TRIALS
BRAINcures
facio therapies
SOM
SUCAMPO
CHapper healthcare
ERGOMED
PSR
EUROMED
maprovider
OXford pharmacogenes
Pharm-Olam
Planning Shop
The Planning Shop
PPI Healthcare Consulting
WEP Clinical
myTomorrows

MEDIA PARTNERS

INDerscience Publishers
Bentham Science
Biocompare
Bio Partner
The Cell Culture Dish
Colorado BioScience Association
GEORGIA Bio
Insight Pharma Reports
Pan European Networks
pharmaIcensing
pharmaVision
Pharma Voice
Personalize My Medicine
Swiss Biotech
Vaccines
ADC Review
Mapi
BioPharma DVE
Check Orphan
Computational and Structural Biotechnology Journal

To exhibit, sponsor or speak, please call Andrew Mears on +44 (0) 207 092 1228 or email andrew.mears@terrapinn.com